- Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
- Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
- Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
- Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
- Lipocine to Present at 36th Annual Roth Conference
- Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
- Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
More ▼
Key statistics
On Wednesday, Lipocine Inc (LPCN:NAQ) closed at 4.44, 92.20% above the 52 week low of 2.31 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.79 |
---|---|
High | 5.02 |
Low | 4.40 |
Bid | 4.38 |
Offer | 4.99 |
Previous close | 4.80 |
Average volume | 278.45k |
---|---|
Shares outstanding | 5.32m |
Free float | 5.15m |
P/E (TTM) | -- |
Market cap | 25.52m USD |
EPS (TTM) | -3.11 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 21:00 BST.
More ▼